Deb Gokie discusses the Arthritis Foundation's inclusive design program, emphasizing its impact on medical device and ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

Pharmaceutical products have long been spared from trade wars due to the potential harms. But Trump's move to increase tariffs on goods from China, including finished drugs and raw ingredients, as ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its expectations for ...

The second cycle of negotiations will take place under President Donald Trump's administration. The U.S. government has said ...

WASHINGTON (Reuters) -President Donald Trump's nominee to lead the agency overseeing Medicare should divest financial ties to ...

These findings are raising concerns among scientists about how climate change and heat waves might be deteriorating bodily ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

Our reporting shows this will be painful for many biopharma companies who rely on funds from the sale of PRVs. Speaking of money, AbbVie and Eli Lilly struck a pair of mid-size deals in hot spaces.

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

They say war is hell - and it looks like millions of American men are about to learn this the hard way (or maybe not exactly the hard way) as Donald Trump's tariffs could massively inflate the price ...